P.015 Monthly migraine days, acute medication use-days, and migraine-specific quality of life in responders to atogepant: a post hoc analysis
| العنوان: | P.015 Monthly migraine days, acute medication use-days, and migraine-specific quality of life in responders to atogepant: a post hoc analysis |
|---|---|
| المؤلفون: | DW Dodick, RB Lipton, SJ Nahas, P Pozo-Rosich, P McAllister, LL Mechtler, E Leroux, J Ma, B Dabruzzo, M Dufek, L Severt, M Finnegan, J Trugman |
| المصدر: | Canadian Journal of Neurological Sciences / Journal Canadien des Sciences Neurologiques. 49:S11-S11 |
| بيانات النشر: | Cambridge University Press (CUP), 2022. |
| سنة النشر: | 2022 |
| مصطلحات موضوعية: | Neurology, Neurology (clinical), General Medicine |
| الوصف: | Background: In phase 3 ADVANCE, atogepant 60mg reduced mean monthly migraine days (MMDs) from 7.8 days (baseline) to 3.0 (weeks 9-12; Δ=−4.7) in the overall episodic migraine population [treatment responders and nonresponders (i.e., marked benefit and minimal benefit)], which obscures information regarding magnitude of treatment effect in these populations. Here, magnitude of treatment effect in atogepant responders and nonresponders is characterized. Methods: Mean MMDs, acute medication use-days (MUDs), and Migraine-Specific Quality of Life-Role Function-Restrictive (MSQ-RFR) scores were calculated in treatment responders (based on MMD percentage reduction) and nonresponders from ADVANCE participants. Results: From baseline to weeks 9-12, ≥50% improvement was achieved by 71% (139/195) of participants. In these responders, MMDs reduced from 7.6 to 1.3 (Δ=−6.3). 50% (97/195) of participants achieved ≥75% response. In this group, MMDs reduced from 7.7 to 0.6 (Δ=−7.1). Atogepant 60mg nonresponders ( |
| تدمد: | 2057-0155 0317-1671 |
| DOI: | 10.1017/cjn.2022.118 |
| URL الوصول: | https://explore.openaire.eu/search/publication?articleId=doi_________::95cf8851a564f61cf4a7943846d83eed https://doi.org/10.1017/cjn.2022.118 |
| Rights: | CLOSED |
| رقم الانضمام: | edsair.doi...........95cf8851a564f61cf4a7943846d83eed |
| قاعدة البيانات: | OpenAIRE |
| تدمد: | 20570155 03171671 |
|---|---|
| DOI: | 10.1017/cjn.2022.118 |